Risk of Liver Damage with Tizanidine
Tizanidine carries a real but relatively low risk of hepatotoxicity, with approximately 5% of patients developing liver enzyme elevations >3× upper limit of normal in controlled trials, and rare cases of severe liver injury including fatal hepatic failure have been reported. 1
Magnitude and Nature of Hepatic Risk
The FDA drug label explicitly warns about hepatotoxicity as a significant adverse effect 1. In controlled clinical studies:
- 5% of tizanidine-treated patients developed ALT/AST elevations >3× ULN (or >2× ULN if baseline was elevated)
- This compares to only 0.4% in control patients
- Most cases are hepatocellular in type rather than cholestatic
- The majority resolve rapidly upon drug discontinuation with no residual problems 1
Severe and Fatal Cases
Three deaths associated with liver failure have been documented in postmarketing surveillance 1:
- A 49-year-old male developed jaundice and hepatomegaly after 2 months on tizanidine 6 mg TID, progressing to multilobular necrosis and death in hepatic coma 10 days after discontinuation
- A patient on tizanidine 4 mg/day plus carbamazepine developed cholestatic jaundice after 2 months and died with pneumonia
- A patient treated for 11 days with tizanidine (also on dantrolene) developed fatal fulminant hepatic failure
Additional case reports document serious hepatotoxicity, including one case requiring rechallenge that confirmed tizanidine as the causative agent 2, and a pediatric case with liver, renal, and cardiovascular failure after overdose 3.
Clinical Monitoring Requirements
The FDA mandates specific monitoring protocols 1:
- Baseline aminotransferase levels before starting therapy
- Regular monitoring during first 6 months: at 1,3, and 6 months
- Periodic monitoring thereafter based on clinical status
- Immediate discontinuation if symptomatic hepatitis develops (nausea, vomiting, anorexia, jaundice)
High-Risk Populations and Contraindications
Tizanidine should be avoided or used with extreme caution in 4, 5:
- Patients with pre-existing hepatic impairment (absolute contraindication per guidelines)
- Patients with renal dysfunction (dose reduction required)
- Concurrent use of CYP1A2 inhibitors (ciprofloxacin and fluvoxamine are absolute contraindications; oral contraceptives, acyclovir, amiodarone, verapamil, cimetidine, and famotidine significantly increase tizanidine levels and hepatotoxicity risk) 5, 6
- Elderly patients due to increased sensitivity 5
Drug Interaction Considerations
A critical case report describes acute hepatitis in a patient initiated on both tizanidine and bortezomib (both CYP1A2 substrates), with potential exacerbation by acyclovir and hydralazine (CYP1A2 inhibitors) 6. This underscores the importance of reviewing all concurrent medications for CYP1A2 interactions.
Clinical Context from Broader Evidence
While guidelines from Mayo Clinic note hepatotoxicity as an adverse effect of tizanidine 4, 5, they still recommend continuing the medication perioperatively, suggesting the risk-benefit ratio is generally acceptable when properly monitored. However, large-scale clinical trials show mild LFT elevations occur occasionally but typically improve with dose reduction or withdrawal 7.
Common Pitfalls to Avoid
- Failing to obtain baseline liver function tests before initiating therapy
- Not recognizing CYP1A2 drug interactions that dramatically increase tizanidine levels and toxicity risk
- Continuing therapy despite symptomatic hepatitis (jaundice, nausea, vomiting, anorexia)
- Inadequate monitoring frequency during the critical first 6 months
- Using tizanidine in patients with pre-existing liver disease without extreme caution